Neal Shore, MD, FACS, discusses the safety profiles reported across the nadofaragene firadenovec, SunRISe-1, and NURE-COMBO trials, highlighting any unexpected toxicities observed with these novel therapies for non-muscle-invasive and muscle-invasive bladder cancer. Additionally, he reviews key limitations of the study designs or patient populations that may impact the interpretation and generalizability of the results from these trials.
A medical expert compares CDK4/6 inhibitors and discusses the importance of monitoring specific parameters, such as ECGs and laboratory tests, to minimize adverse events associated with each drug.
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,.
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - .
C++ safety, in context herbsutter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from herbsutter.com Daily Mail and Mail on Sunday newspapers.